Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
-
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
-
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
-
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
-
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
-
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
-
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
-
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
Trading Information
- Previous Close Price
- $156.42
- Day Range
- $156.25–159.99
- 52-Week Range
- $122.13–169.45
- Bid/Ask
- $144.85 / $176.99
- Shares Outstanding
- 100.55M
- Market Cap
- $16.04B
- Volume/Avg
- 566,021 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 20.91
- Price/Sales
- 5.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.45%
Company Profile
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,000
- Website
- https://www.neurocrine.com
Competitors
Valuation
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.91 | 11.82 | 10.51 |
Price/Book Value | 4.72 | 4.90 | 1.27 |
Price/Sales | 5.29 | 2.33 | 1.96 |
Price/Cash Flow | 16.89 | 13.49 | 9.00 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Quick Ratio | 2.51 | 0.53 | 0.20 |
Current Ratio | 2.93 | 1.01 | 1.01 |
Interest Coverage | — | 2.51 | 11.82 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 18.32% | 8.61% | 7.49% |
Return on Equity (Normalized) | 26.30% | 47.02% | 13.70% |
Return on Invested Capital (Normalized) | 23.00% | 16.91% | 10.47% |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Ycqgtldl | Kyvwtl | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Yphjfptbl | Gxmbjc | $40B | |||
| Haleon PLC ADR
HLN
| Jncwhlqn | Rtn | $40B | |||
| Zoetis Inc Class A
ZTS
| Sxxlwdqfr | Gzsx | $33B | |||
| Viatris Inc
VTRS
| Yhqdtvly | Sqtt | $19B | |||
| Elanco Animal Health Inc
ELAN
| Kdf | Kymr | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Pqczmvz | Qsj | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Tftwgfy | Gssm | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Hghfssy | Yrslq | $2B | |||
| Perrigo Co PLC
PRGO
| Pxcwbbkl | Sjt | $2B |
United States